Search Press releases

31 Jan 2025

RYSTIGGO[®](rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods

Read More
15 Jan 2025

UCB showcases decade of growth and Patient Value Strategy driving differentiated innovation

Read More
9 Jan 2025

UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform

Read More
2 Jan 2025

Transparency notification Wellington

Read More
16 Dec 2024

Findings from minzasolmin proof-of-concept ORCHESTRA study shape next steps in UCB Parkinson’s research program

Read More
29 Nov 2024

UCB Focuses on New Launch and Completes Divestment of Mature Product Business in China

Read More

Stay up-to-date on the latest news and information from UCB